Nov 06, 2024 / 01:00PM GMT
Operator
Thank you and good afternoon. Good morning everyone to the Medivir Q3 report and we are thrilled to sort of walk you through sort of the events of the past quarter. We've seen a lot of progress in our, our lead asset FSRS and especially over the last couple of weeks. So we look forward to going through the the bigger events as we aim to bring the first oral liver targeted treatment for patients with advanced liver cancer to market.
And in terms of key events during the past quarter, as we have presented earlier in September at the ESMO Congress, we presented the mature data set from an efficacy point of view, confirming the promise of improved outcome of the combination with Fosroc and Lyve showing among other things, a 10.9 months sort of mature data set with regards to time to progression, sort of substantially longer than, than what can be expected with current treatment alternatives in second line. Sort of further strengthening our belief in the combination as a treatment option for the future P I will go through in a bit more detail sort of what we shared at SB and feedback we received from
Q3 2024 Medivir AB Earnings Call Transcript
Nov 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers